Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
CSL Ltd. Acquires Talecris
 

CSL Limited, the Australia-based parent company of CSL Behring, is buying Talecris Biotherapeutics Holdings Corp for $3.1 billion.

Talecris Biotherapeutics currently manufactures Koāte-DVI®, a plasma-derived factor VIII product for the treatment of bleeding episodes in patients with hemophilia A. The company also manufactures therapies for individuals with immune deficiency disorders and antithrombin III deficiency, a clotting disorder.

CSL Limited has over 9,000 employees in over 27 countries including major facilities in Australia, Germany, Switzerland and the U.S. CSL Behring, headquartered in King of Prussia, PA, specializes in plasma protein therapies.

Also in August, CSL Behring announced the availability of a new wireless patient data management tool called the HeliTraxSM System. Patients use the hand-held Helixate® FS device to transmit data to their hemophilia treatment center. According to CSL Behring, the new system is intended to improve “patient-physician communications” and treatment management.

Source: Reuters, August 13, 2008 and CSL Behring press release dated August 25, 2008